DISARM also urges increased Medicare reimbursement payments to hospitals for using advanced antibiotics to fight superbugs.
In an email to CNBC, Roskam's office said the current Medicare reimbursement policy for hospitals pays around "$10 or less for each antibiotic that could cost hundreds of dollars to use.. so hospitals tend to use them less, which results in companies not developing them."
The higher payments would be revenue-neutral for Medicare, with eventual savings through shorter hospital stays and lower readmission rates, according to Roskam's office. The exact increase would need to be worked out between drug companies and insurers.
The hope is that hospitals will use more of those expensive drugs, and then pharmaceutical companies will produce new ones—something they're not doing much of now. Experts say only three new antibiotics have entered the marketplace in the last five years.
Read MoreOregon quits Obamacare biz; feds pick up the slack
"It's crucial to get the Medicare payment restructure in place," said Barrett Thornhill, executive director of the Antimicrobial Innovation Alliance (AIA), a coalition of pharmaceutical companies and a major backer of DISARM.
"It's very expensive to develop the stronger antibiotics," said Dr. Marco Taglietti, executive vice president of drug development and research and chief medical officer at Forest Laboratories, which is a member of AIA.
"DISARM would have less constraint when it comes to tight financial rules and making sure hospitals feel comfortable to explore using the drugs," explained Tagiletti, who said Forest Labs has one strong antibiotic on the market, Teflaro, and is developing another.